SMMT - Summit spikes as Citi launches at Buy on lead asset
2024-05-07 13:56:20 ET
More on Summit Therapeutics
- Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
- Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
- Summit Therapeutics Inc. (SMMT) Q4 2023 Earnings Call Transcript
- Summit Therapeutics stock plunges 28% amid financial updates
- Seeking Alpha’s Quant Rating on Summit Therapeutics